
<h3>BIBLIOGRAFÍA</h3>

    <ol>
        <li>Tsai HM. A mechanistic approach to the diagnosis and management of atypical hemolytic uremic syndrome. Transfus Med Rev 2014;28(4):187-97.</li>
        <li>Scully M, Cataland S, Coppo P, de la Rubia J, Friedman KD, Kremer Hovinga J, et al; International Working Group for Thrombotic Thrombocytopenic Purpura. Consensus on the standardization of terminology in thrombotic thrombocytopenic purpura and related thrombotic microangiopathies. J Thromb Haemost 2017;15(2):312-22.</li>
        <li>Sadler JE. What’s new in the diagnosis and pathophysiology of thrombotic thrombocytopenic purpura. Hematology Am Soc Hematol Educ Program 2015; 2015: 631-6.</li>
        <li>Bitzan M, Bickford BB, Foster GH. Verotoxin (Shiga toxin) sensitizes renal epithelial cells to increased heme toxicity: possible implications for the hemolytic uremic syndrome. J Am Soc Nephrol 2004;15:2334-43.</li>
        <li>Franchini M. Atypical hemolytic uremic syndrome: from diagnosis to treatment. Clin Chem Lab Med 2015;53(11):1679-88.</li>
        <li>Alwan F, Vendramin C, Vanhoorelbeke K, Langley K, McDonald V, Austin S, et al. Presenting ADAMTS13 antibody and antigen levels predict prognosis in immune-mediated thrombotic thrombocytopenic purpura. Blood 2017;130(4):466-71.</li>
        <li>Lotta LA, Wu HM, Mackie IJ, Noris M, Veyradier A, Scully MA, et al. Residual plasmatic activity of ADAMTS13 is correlated with phenotype severity in congenital thrombotic thrombocytopenic purpura. Blood 2012;120(2):440-8.</li>
        <li>Contreras E, de la Rubia J, del Río Garma J, Díaz-Ricart M, García-Gala JM, Lozano M. Diagnostic and therapeutic guidelines of thrombotic microangiopathies of the Spanish Apheresis Group. Med Clin (Barc) 2015;144(7):331.e1-331.e13.</li>
        <li>Pereira A, Mazzara R, Monteagudo J, Sanz C, Puig L, Martínez A, et al. Thrombotic thrombocytopenic purpura/hemolytic uremic syndrome: a multivariate analysis of factors predicting the response to plasma exchange. Ann Hematol 1995;70(6):319-23.</li>
        <li>Rock GA, Shumak KH, Buskard NA, et al. Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. New Engl J Med 1991;325:393-7.</li>
        <li>Del Río-Garma J, Álvarez-Larrán A, Martínez C, Muncunill J, Castellà D, de la Rubia J, et al. Methylene blue-photoinactivated plasma versus quarantine fresh frozen plasma in thrombotic thrombocytopenic purpura: a multicentric, prospective cohort study. Br J Haematol 2008;143(1):39-45.</li>
        <li>Bell WR, Braine HG, Ness PM, Kickler TS. Improved survival in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Clinical experience in 108 patients. N Engl J Med 1991;325(6):398-403.</li>
        <li>Swisher KK, Terrell DR, Veseley SK, Kremer Hovinga JA, Lämmle B, George JN, et al. Clinical outcomes after platelet transfusions in patients with thrombotic thrombocytopenic purpura. Transfusion 2009;49:873-87.</li>
        <li>De la Rubia J, Moscardó F, Gómez MJ, Guardia R, Rodríguez P, Sebrango A, et al. Efficacy and safety of rituximab in adult patient with idiopathic relapsing or refractory thrombotic thrombocytopenic purpura: results of a Spanish multicenter Study. Transf Apher Science 2010;43:299-302.</li>
        <li>Westwood JP, Webster H, Mcguckin S, McDonald V, Machin SJ, Scully M, et al. Rituximab for thrombotic thrombocytopenic purpura: benefit of early administration during acute episodies and use of prophylaxis to prevent relapse. J Thromb Haemost 2013;11:481-90.</li>
        <li>Kappers-Klunne MC, Wijermans P, Fijnheer R, Croockewit AJ, van der Holt B, de Wolf JT, et al. Splenectomy for the treatment of thrombotic thrombocytopenic purpura. Br J Haematol 2005;130(5):768-76.</li>
        <li>Patriquin CJ, Thomas MR, Dutt T, McGuckin S, Blombery PA, Cranfield T, et al. Bortezomib in the treatment of refractory thrombotic thrombocytopenic purpura. Br J Haematol 2016;173(5):779-85.</li>
        <li>Peyvandi F, Scully M, Kremer Hovinga JA, Knöbl P, Cataland S, de Beuf K, et al. Caplacizumab reduces the frequency of major thromboembolic events, exacerbations and death in patients with acquired thrombotic thrombocytopenic purpura. J Thromb Haemost 2017;15(7):1448-52.</li>
        <li>Scully M, Thomas M, Underwood M, Watson H, Langley K, Camilleri RS, et al. Thrombotic thrombocytopenic purpura and pregnancy: presentation, management, and subsequent pregnancy outcomes. Blood 2014;124(2):211-9.</li>
        <li>Legendre CM, Licht C, Loirat C. Eculizumab in atypical hemolytic-uremic syndrome. N Engl J Med 2013;369:1379-80.</li>
    </ol>